Selected highlights of ECTRIMS 2016
London, UK – 14-17 September 2016
31 slides
Click here to download the ECTRIMS 2016 Slide Deck
Scientific review:
Dr. Daniel Selchen, Chief of Neurology, St. Michael’s Hospital, University of Toronto, Toronto, Canada
Preliminary results from the EXPAND trial show that siponimod significantly reduces disability progression confirmed at three and six months, according to results presented at the annual meeting of the European Committee for Treatment and Research in MS (Kappos et al. ECTRIMS 2016; abstract 250). Read More
Thursday Edition
Friday Edition
European Committee for Treatment and Research in MS (ECTRIMS), London UK, 14-17 September 2016 – The following summarizes recent studies in primary- and secondary-progressive MS. Read More
Thursday Edition
Saturday Edition
European Committee for Treatment and Research in MS (ECTRIMS), London UK, 14-17 September 2016
The following summarizes studies of disease-modifying therapies presented at ECTRIMS 2016. Read More